Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. (9th August 2021)

• Record Type: Journal Article
• Authors: Salem, Joe-Elie; Nguyen, Lee S; Moslehi, Javid J; Ederhy, Stéphane; Lebrun-Vignes, Bénédicte; Roden, Dan M; Funck-Brentano, Christian; Gougis, Paul
• Is Part Of: European heart journal. Volume 42:Number 38(2021)
• Page Start: 3915
• Page End: 3928
• Publication Date: 2021-08-09
• Subjects: Disproportionality analysis -- Anticancer drugs -- Long QT -- Ventricular arrhythmias -- Pharmacovigilance -- Torsade de pointes; Cardiology -- Periodicals; Heart -- Diseases -- Periodicals; 616.12005
• DOI: 10.1093/eurheartj/ehab362
• Languages: English
• ISSNs: 0195-668X

Abstract

Abstract: Aims: With the explosion of anticancer drugs, an emerging concern is the risk for drug-induced sudden death (SD) via ventricular arrhythmias (VA). Methods and results: We used the international pharmacovigilance database VigiBase ( n = 18 441 659 reports) to compare drug-induced long QT (diLQT, n = 18 123) and VA ( n = 29 193) including torsade de pointes (TdP, n = 8163) reporting for 663 anticancer drugs vs. all other drugs until 01/01/2019. The analysis used the 95% lower-end credibility interval of the information component (IC025 ), an indicator for disproportionate Bayesian reporting; significant when IC025 >0. There were 2301 reports (13.8% fatal) for 40 anticancer drugs significantly associated with diLQT (with 27 also associated with VA or SD) and 9 drugs associated with VA without diLQT. Half of these (46.9%, 23/49) were associated with SD. Most (41%, 20/49) were kinase inhibitors, 8% (4/49) were hormonal therapies, 6% (3/49) were immunotherapies, 24% (12/49) were cytotoxics, and 20% (10/49) were miscellaneous. In VigiBase, reports of diLQT, TdP, or VA increased from 580 in the period 1967–83 to 15 070 in 2014–18 with the proportion related to anticancer drugs increasing from 0.9% (5/580) to 14.0% (2115/15 070) ( P < 0.0001). Concordance between these VigiBase signals and data concerning diLQT and VA/TdP identified in CredibleMeds or US Food and Drug Administration (FDA) labels was moderate (κ = 0.47 and 0.40, P < 0.0001). Twenty-three drugs represent new signals, while 24 flagged by CredibleMeds or FDA had no signal in VigiBase. A three-level SD risk stratification relying on isolated long QT (low risk), associated with VA without SD (moderate risk), and VA with SD (high risk) is proposed. Conclusion: This list of liable anticancer drugs may prove useful for physicians and regulatory authorities to re-evaluate cardiac monitoring requirements. Clinical trial registration: NCT03530215. Graphical Abstract: